Compare MRKR & LRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRKR | LRE |
|---|---|---|
| Founded | 1999 | 2001 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7M | 17.7M |
| IPO Year | 2010 | 2022 |
| Metric | MRKR | LRE |
|---|---|---|
| Price | $1.40 | $1.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 54.6K | 8.0K |
| Earning Date | 05-14-2026 | 07-30-2015 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $936.27 | N/A |
| P/E Ratio | ★ N/A | $3.16 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.81 | $1.00 |
| 52 Week High | $2.46 | $2.86 |
| Indicator | MRKR | LRE |
|---|---|---|
| Relative Strength Index (RSI) | 62.15 | 51.14 |
| Support Level | $1.35 | $1.20 |
| Resistance Level | $1.54 | $1.37 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 88.76 | 54.17 |
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa Prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment units to individual customers in Japan and Dallas, Texas. Its revenue is predominantly generated from developing and selling single-family homes and condominiums, hotel operations, and residential leasing. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.